Samsung Biologics Achieves 'Negligible Risk' Rating in ESG Assessment

Samsung Biologics, a prominent player in the biopharmaceutical sector, has achieved a 'Negligible Risk' rating in the latest Sustainalytics ESG assessment. This rating signifies the company's dedication to environmental, social, and governance standards, positioning it favorably within the industry.

The assessment, conducted by Morningstar Sustainalytics, evaluated approximately 16,000 companies globally, with Samsung Biologics scoring 9.0. This rating reflects a significant advancement from its previous 'Low Risk' classification, now placing it among the top 0.5% of companies in the pharmaceuticals industry.

John Rim, President and CEO of Samsung Biologics, emphasized the importance of effective risk management, stating, "This recognition demonstrates the progress we have made in embedding responsible practices across our business." The company has implemented various initiatives to enhance its ESG management, including improved environmental auditing and business ethics.

This achievement follows other notable accolades, including an 'A' rating in the 2026 MSCI ESG Ratings assessment and the EcoVadis Platinum Sustainability Rating earlier this year. Samsung Biologics continues to invest in new capabilities to ensure operational excellence and sustainable business practices.